GL
VRTX icon

GLG LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

GLG LLC’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$4.29M Hold
28,609
– – 0.31% 89
2017
Q3 		$4.35M Sell
28,609
-2,660
-9% -$400K 0.28% 98
2017
Q2 		$4.03M Buy
31,269
+7,528
+32% +$906K 0.25% 116
2017
Q1 		$2.6M Buy
23,741
+9,969
+72% +$878K 0.14% 189
2016
Q4 		$1.01M Sell
13,772
-38,125
-73% -$3.1M 0.07% 275
2016
Q3 		$4.53M Sell
51,897
-4,306
-8% -$407K 0.32% 81
2016
Q2 		$4.83M Sell
56,203
-3,045
-5% -$263K 0.36% 80
2016
Q1 		$4.71M Buy
59,248
+22,794
+63% +$2.06M 0.29% 97
2015
Q4 		$4.59M Sell
36,454
-110,262
-75% -$13.3M 0.27% 99
2015
Q3 		$15.3M Sell
146,716
-762
-0.5% -$97.9K 0.38% 67
2015
Q2 		$18.2M Buy
147,478
+125,493
+571% +$15.8M 0.39% 70
2015
Q1 		$2.59M Buy
21,985
+8,274
+60% +$991K 0.07% 289
2014
Q4 		$1.63M Sell
13,711
-116,097
-89% -$13.1M 0.05% 358
2014
Q3 		$14.6M Buy
129,808
+104,544
+414% +$9.95M 0.39% 72
2014
Q2 		$2.39M Buy
25,264
+4,799
+23% +$337K 0.07% 331
2014
Q1 		$1.45M Buy
+20,465
New +$1.62M 0.05% 393

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

GLG LLC's VRTX Position: Q4 2017 in Review

GLG LLC held its Vertex Pharmaceuticals (VRTX) position steady in Q4 2017 at 28,609 shares worth $4.29M. The position accounts for 0.31% of the portfolio, ranked #89.

GLG LLC first reported a position in VRTX in Q1 2014 and has held it in 16 quarters since. The position peaked at $18.2M in Q2 2015. 644 funds tracked by Wall St. Rank hold VRTX as of Q4 2017.

  • GLG LLC held 28,609 shares of Vertex Pharmaceuticals worth $4.29M as of Q4 2017.
  • GLG LLC left its Vertex Pharmaceuticals share count unchanged in Q4 2017.
  • Vertex Pharmaceuticals made up 0.31% of GLG LLC's portfolio in Q4 2017, its #89 holding.
  • GLG LLC first reported a position in Vertex Pharmaceuticals in Q1 2014 and has held it in 16 quarters since.
  • GLG LLC's Vertex Pharmaceuticals position peaked at $18.2M in Q2 2015.
  • 644 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2017.

Based on GLG LLC's 13F filing for Q4 2017, filed 14 Feb 2018.